Literature DB >> 31698920

Acceptability of electronic nicotine delivery systems (ENDS) among HIV positive smokers.

Jessica Yingst1, Jonathan Foulds1, John Zurlo2, Michael B Steinberg3, Thomas Eissenberg4, Ping Du1,2.   

Abstract

Electronic nicotine delivery systems (ENDS) have the potential to help smokers living with HIV/AIDS (PLWHA) to reduce harms from tobacco use. However, little is known about ENDS use among PLWHA. This study's aim was to evaluate the acceptability of two types of ENDS among PLWHA not planning to quit smoking. The study utilized a cross-over design where participants used two ENDS in a random order as smoking substitutes during two use periods separated by 7 days. Exhaled carbon monoxide (CO) was analyzed and participants reported daily cigarette and ENDS use and completed ratings on ENDS acceptability. Participants (n = 17) were a mean age of 49.1 years (SD = 8.8), were 53% white, and 59% male. All participants had controlled HIV disease status. Participants smoked a mean of 16.9 (SD = 7.9) CPD at baseline. Overall, CPD significantly decreased during both ENDS use periods (p < .01) but there were no differences in reduction between the different devices. CO decreased from baseline to follow-up only during the button-activated ENDS use period (p = .03), but there were no differences between ENDS devices. There were no significant differences in ratings of acceptability between ENDS devices. These results suggest that ENDS could be a harm reduction tool for smokers with HIV.

Entities:  

Keywords:  Electronic cigarettes; HIV; tobacco use

Mesh:

Year:  2019        PMID: 31698920      PMCID: PMC7202989          DOI: 10.1080/09540121.2019.1687835

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  25 in total

1.  Tobacco use and readiness to quit smoking in low-income HIV-infected persons.

Authors:  Jack E Burkhalter; Carolyn M Springer; Rosy Chhabra; Jamie S Ostroff; Bruce D Rapkin
Journal:  Nicotine Tob Res       Date:  2005-08       Impact factor: 4.244

2.  Electronic cigarette user plasma nicotine concentration, puff topography, heart rate, and subjective effects: Influence of liquid nicotine concentration and user experience.

Authors:  Marzena Hiler; Alison Breland; Tory Spindle; Sarah Maloney; Thokozeni Lipato; Nareg Karaoghlanian; Alan Shihadeh; Alexa Lopez; Carolina Ramôa; Thomas Eissenberg
Journal:  Exp Clin Psychopharmacol       Date:  2017-10       Impact factor: 3.157

3.  Trends in cigarette smoking among adults with HIV compared with the general adult population, United States - 2009-2014.

Authors:  Emma L Frazier; Madeline Y Sutton; John T Brooks; R Luke Shouse; John Weiser
Journal:  Prev Med       Date:  2018-03-14       Impact factor: 4.018

Review 4.  Electronic cigarettes: what are they and what do they do?

Authors:  Alison Breland; Eric Soule; Alexa Lopez; Carolina Ramôa; Ahmad El-Hellani; Thomas Eissenberg
Journal:  Ann N Y Acad Sci       Date:  2016-01-15       Impact factor: 5.691

5.  E-cigarette versus nicotine inhaler: comparing the perceptions and experiences of inhaled nicotine devices.

Authors:  Michael B Steinberg; Mia Hanos Zimmermann; Cristine D Delnevo; M Jane Lewis; Parth Shukla; Elliot J Coups; Jonathan Foulds
Journal:  J Gen Intern Med       Date:  2014-05-15       Impact factor: 5.128

6.  Views of Experienced Electronic Cigarette Users.

Authors:  Raman Baweja; Katherine M Curci; Jessica Yingst; Susan Veldheer; Shari Hrabovsky; Stephen J Wilson; Travis T Nichols; Thomas Eissenberg; Jonathan Foulds
Journal:  Addict Res Theory       Date:  2015-09-02

7.  EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study.

Authors:  Pasquale Caponnetto; Davide Campagna; Fabio Cibella; Jaymin B Morjaria; Massimo Caruso; Cristina Russo; Riccardo Polosa
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

8.  Cigarette smoking is associated with high HIV viral load among adults presenting for antiretroviral therapy in Vietnam.

Authors:  Todd M Pollack; Hao T Duong; Thuy T Pham; Cuong D Do; Donn Colby
Journal:  PLoS One       Date:  2017-03-07       Impact factor: 3.240

9.  Tobacco use among people living with HIV: analysis of data from Demographic and Health Surveys from 28 low-income and middle-income countries.

Authors:  Noreen D Mdege; Sarwat Shah; Olalekan A Ayo-Yusuf; James Hakim; Kamran Siddiqi
Journal:  Lancet Glob Health       Date:  2017-06       Impact factor: 26.763

10.  Nicotine absorption during electronic cigarette use among regular users.

Authors:  Jessica M Yingst; Jonathan Foulds; Susan Veldheer; Shari Hrabovsky; Neil Trushin; Thomas T Eissenberg; Jill Williams; John P Richie; Travis T Nichols; Stephen J Wilson; Andrea L Hobkirk
Journal:  PLoS One       Date:  2019-07-25       Impact factor: 3.240

View more
  4 in total

Review 1.  Electronic cigarettes for smoking cessation.

Authors:  Jamie Hartmann-Boyce; Hayden McRobbie; Ailsa R Butler; Nicola Lindson; Chris Bullen; Rachna Begh; Annika Theodoulou; Caitlin Notley; Nancy A Rigotti; Tari Turner; Thomas R Fanshawe; Peter Hajek
Journal:  Cochrane Database Syst Rev       Date:  2021-09-14

2.  Tobacco Use and Treatment of Tobacco Dependence Among People With Human Immunodeficiency Virus: A Practical Guide for Clinicians.

Authors:  Krishna P Reddy; Gina R Kruse; Stephanie Lee; Jonathan Shuter; Nancy A Rigotti
Journal:  Clin Infect Dis       Date:  2022-08-31       Impact factor: 20.999

3.  Electronic cigarettes for smoking cessation.

Authors:  Jamie Hartmann-Boyce; Hayden McRobbie; Nicola Lindson; Chris Bullen; Rachna Begh; Annika Theodoulou; Caitlin Notley; Nancy A Rigotti; Tari Turner; Ailsa R Butler; Thomas R Fanshawe; Peter Hajek
Journal:  Cochrane Database Syst Rev       Date:  2021-04-29

Review 4.  An update on drug-drug interactions between antiretroviral therapies and drugs of abuse in HIV systems.

Authors:  Nuti Desai; Leah Burns; Yuqing Gong; Kaining Zhi; Asit Kumar; Nathan Summers; Santosh Kumar; Theodore J Cory
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-08-31       Impact factor: 4.481

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.